2020. Evidence level for effectiveness of glucagon-like peptide-1 receptor agonists respectively sodium glucose co-transporter-2 inhibitors for mitochondrial diabetes is low. Innovative Journal of Medical and Health Sciences. 10, 06 (Jun. 2020), 959–960.